Alnylam Pharmaceuticals, Inc.
Asset & Liabilities Breakdown
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
FY2014
FY2013
FY2012
FY2011
FY2010
FY2009
Asset Breakdown FY2021
Total Assets: $3.64B
Liabilities Breakdown FY2021
Total Liabilities: $3.06B
Asset Breakdown
Total Assets: $3.64B
| Line Item | Value | % of Total |
|---|---|---|
| Cash & Equivalents | $820.0M | 22.5% |
| Accounts Receivable | $198.6M | 5.5% |
| Inventory | $86.4M | 2.4% |
| Property, Plant & Equipment | $502.0M | 13.8% |
| Goodwill | $0 | 0.0% |
| Intangible Assets | $0 | 0.0% |
| Other Assets | $2.04B | 55.9% |
Liabilities Breakdown
Total Liabilities: $3.06B
| Line Item | Value | % of Total |
|---|---|---|
| Accounts Payable | $73.4M | 2.4% |
| Long-Term Debt | $0 | 0.0% |
| Other Liabilities | $2.98B | 97.6% |